HIV biology and antiretroviral therapy; basic and clinical pharmacology of antiretroviral drugs.
Flexner C. HIV drug development: the next 25 years (2007). Nature Reviews Drug Discovery; 6: 959-966.
Gulick RM, Su Z, Flexner C, Hughes M, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves W, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR for the ACTG 5211 Team (2007). Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: ACTG 5211. J Infect Dis; 196: 178-180.
Cao YJ, Flexner CW, Dunaway S, Park JG, Klingman K, Wiggins I, Conley J, Radebaugh C, Kashuba AD, Macfarland R, Becker S, Hendrix CW (2008). Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrob Agents Chemother; 52:1630-1634.
Dooley K, Flexner C, Andrade ASA (2008). Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis; 198: 948-961.
Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D, AIDS Clinical Trials Group A5073 Study Team (2009). Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-na´ve HIV-1 infected patients: a randomized trial. Arch Intern Med; 169:1224-1232.
Return to Faculty Home